Despite implementation of targeted therapies, the overall survival for metastatic clear cell renal cell carcinoma (ccRCC) is poor after 5 year follow-up. Thus, novel tumorassociated markers, which may predict patient outcome and may serve as promising therapeutic targets, are of interest. Monocarboxylate transporter 4 (MCT4) mediates lactate efflux, which is essential for energy metabolism especially in tumor cells and thereby contributes to anti-apoptotic effects in tumor biology. In this study we report that MCT4 protein is overexpressed in >85% of ccRCC and regulated by DNA methylation of the SLC16A3 promoter resulting in adverse cancer specific outcome. 
Introduction:
Clear cell renal cell carcinoma (ccRCC) accounts for approximately 80% of renal carcinomas (1) (2) (3) . The only curative treatment for localized ccRCC is partial or radical nephrectomy. However, patients remain at a considerable risk of recurrence and development of metastases after surgery (4) , subsequently resulting in an overall survival for metastatic ccRCC of about 20% after 5 year follow-up. This poor survival rate is determined by resistance to radiation and chemotherapy and limited applicability of immunotherapy due to low response rates and severe toxicity (3, 5) .
Despite remarkable progress in the field of targeted therapies, identification of tumorassociated markers, which are able to predict patient outcome and at best may serve as target for ccRCC therapy, is of major interest.
Since several findings suggest that ccRCC is mainly a metabolic disease (6), tumor-specific changes in metabolic enzymes or transport proteins may provide novel therapeutic opportunities. Recent studies identified the monocarboxylate transporter 4 (MCT4) as metabolic target in a variety of tumors (e.g. colon cancer, breast cancer (7, 8) ). MCT4 (encoded by the SLC16A3 gene) mediates the H + -coupled transport of monocarboxylates, preferentially lactate, across the plasma membrane. Especially in highly glycolytic cells, like tumor cells, lactate efflux is essential for energy metabolism in order to ensure the progression of glycolysis and for pH regulation to prevent intracellular acidification (9, 10) . Genome-wide siRNA screening studies in a ccRCC cell line (11) demonstrated that MCT4 may represent a promising metabolic key protein in ccRCC. Moreover, MCT4 mediated lactate efflux, explored in RCC cells by hyperpolarized 13C-pyruvate magnetic resonance, was significantly higher in metastatic RCC cells (12) . However, detailed analyses not only of its expression, but more importantly of the regulation of MCT4 in ccRCC are limited. Author Manuscript Published OnlineFirst on July 23, 2013; DOI: 10.1158/1078-0432.CCR- Interestingly, in addition to the well-established relationship of HIF deregulation through VHL loss, genetic studies of ccRCC tumors identified mutations in genes encoding epigenetic regulators, like PBRM1 or JARID1C (13) . Accordingly, epigenetic modifications, like DNA methylation seem to be important for gene regulation in ccRCC (14, 15) . While upregulation of MCT4 by hypoxia through a HIF1alpha mediated mechanism has been demonstrated in HeLa cell line (16) , the epigenetic regulation of MCT4 in ccRCC has not yet been reported and may offer clue to novel therapeutic strategy.
We therefore performed comprehensive analyses of MCT4 expression on protein and mRNA level in independent cohorts of ccRCC patients and demonstrated significant associations with clinicopathological features and patient outcome. We elucidated DNA methylation in the SLC16A3 promoter region as underlying mechanism for expression differences of MCT4 in ccRCC, which was confirmed by in vitro cell culture experiments. Based on an independent ccRCC validation cohort we provided first evidence for single CpG sites in the SLC16A3 promoter as novel epigenetic markers for clinical outcome in ccRCC.
Research. 
Material and Methods: Supplementary Materials and Methods
A detailed description of the materials and methods used in the present study is given in the Supplementary Data.
Patient cohorts
Two independent retrospective cohorts (TuCP1 and TuCP2) of ccRCC patients treated at the Department of Urology, University Hospital Tuebingen, Germany, were TCGA-cohort are summarized in Table 1 . Processed data sets were obtained from the TCGA Data Portal (http://tcga-data.nci.nih.gov/tcga/) using the Data Browser tool.
MCT4 immunohistochemical staining
Tissue microarray slides containing ccRCC and corresponding non-tumor tissue sections were processed as described (17) and immunostained using an antibody against MCT4 (Santa Cruz Biotechnology, Santa Cruz, USA). The slides were scanned using a digital Mirax scanner (Carl Zeiss, MicroImaging, Jena, Germany). 
RNA isolation and quantification
For details see Supplementary Data.
DNA methylation analyses
For quantitative DNA methylation analyses, matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was applied (18) . Mass spectra were obtained using the MassARRAY compact system and evaluated using the EpiTYPER 1.0 software. Details see Supplementary Data.
SLC16A3 promoter reporter analysis
The influence of DNA methylation on SLC16A3 promoter activity was analysed in an in vitro cell culture system using a dual-reporter assay. In brief, SLC16A3 promoter reporter constructs, cloned into the pCpGfree basic reporter vector (Invivogen, San Results:
Study population
Two independent cohorts of ccRCC patients (TuCP1 and TuCP2) from the University Hospital Tuebingen were investigated. Characteristics of these two cohorts TuCP1 (n=207) and TuCP2 (n=64) are summarized in Table 1 . Median follow-up times of patients in TuCP1 and TuCP2 were 5.9 and 2.3 years, respectively. Additionally, we investigated a third, independent cohort of ccRCC patients from TCGA (n=502, Table   1 ). Overall, the cohorts were similar, but some differences did exist, such as grading Table S1 ). Meier analysis based on optimal cutoffs determined by conditional interference tree models revealed that patients with low MCT4 expression in ccRCC had an increased cancer-specific survival time compared to patients with high expression levels ( Fig.1C ) had a significantly higher risk for cancer-related death.
MCT4 protein expression in ccRCC correlates

MCT4 mRNA expression is increased in ccRCC, whereas SLC16A3 promoter
DNA methylation at single CpG sites is reduced in ccRCC and correlates with patient survival
For validation of the expression differences between ccRCC and non-tumor kidney tissue on mRNA level, mRNA expression of MCT4 was evaluated using RNA-seq data from the independent ccRCC TCGA-cohort. As illustrated in Figure 2A ). Again, restriction of analyses to patients without metastatic ccRCC did not substantially change the observed results (data not shown). For the TCGA-cohort only data for overall survival and not for cancer-specific survival were available.
SLC16A3 promoter DNA methylation at single CpG sites correlates with MCT4 protein expression, clinicopathological features and survival
Finally, we validated our results in a third independent cohort of 64 matching ccRCC and non-tumor tissues (TuCP2) on mRNA, and protein expression level, as well as on DNA methylation level. Again, MCT4 protein as well as mRNA expression were significantly higher in ccRCC compared with non-tumor kidney ( Fig.3A and 3B ).
MCT4 mRNA expression was normalized to Dipeptidyl-peptidase 4 (DPP4). The highly variable MCT4 mRNA and protein expression correlated significantly in ccRCC tissue (r S =0.34, P=0.0099) (Supplementary Fig.S2C ). Moreover, the same trends for the associations between MCT4 protein expression and clinicopathological parameters as in the TuCP1-cohort were observed, but correlations did not reach comparable high statistical significance due to the smaller sample size (Supplementary Table S4 ). With respect to clinical outcome, high MCT4 protein expression in tumor tissue was moderately associated with inferior cancer-specific survival (P[log-rank]=0.175, cutoff determined by conditional interference tree, Supplementary Fig.S3 ). DNA methylation at the SLC16A3 promoter was assessed in the TuCP2-cohort using MALDI-TOF MS (Fig.3C) . The DNA methylation pattern quantified at each analyzed CpG site in normal (red) and ccRCC (blue) tissue showed significantly decreased DNA methylation levels in specific areas of the SLC16A3 promoter in ccRCC compared with non-tumor tissue (Fig.3C) . Of note, investigation of DNA methylation by MALDI-TOF MS allowed a more comprehensive coverage and quantification of CpG sites in the SLC16A3 promoter region compared to the genome-wide array analysis performed in the TCGA cohort (see Supplementary   Table S3 ). Again, DNA methylation at individual CpG sites in the validation cohort (TuCP2), quantified by MALDI-TOF MS correlated significantly inverse with MCT4 mRNA and protein expression (Supplementary Fig.S2C and S2D ). In particular, the percentage of DNA methylation at four specific CpG sites showed significant inverse correlation with MCT4 protein expression in ccRCC even after adjustment for multiple testing ( Supplementary Fig.S2D ).
By correlation analysis of the percentage of DNA methylation of the tumor tissue with clinicopathological parameters, the CpG unit 05_CpG_8.9 revealed significant associations (Table 2 ). This CpG unit is located in close proximity to cg18345635 (Supplementary Table S3 ), which was associated with overall survival and clinicopathological features in the TCGA-cohort (Table 2 ). Higher methylation values at 05_CpG_8.9 in tumor tissue were significantly associated with prolonged survival ( Fig.3D; HR=0 
Dual-reporter gene assays support regulation of MCT4 by DNA methylation
To determine the influence of DNA methylation on SLC16A3 promoter activity, we used different promoter/reporter fusion plasmids containing either methylated or mock-methylated SLC16A3 promoter fragments for promoter reporter assays (Fig.4) .
These constructs were then transfected together with the control vector, constitutively expressing firefly luciferase for normalization, into four different RCC cell lines (Caki1, Caki2, A498, 786-O) and subsequently promoter activities were measured. The influence of DNA methylation on SLC16A3 promoter activity by a dual-reporter gene assay confirmed that reporter constructs with a mock-methylated SLC16A3 promoter fragment showed significantly higher promoter activity than constructs with a methylated SLC16A3 promoter, even in the smaller construct and independent of the VHL status of the cells (Fig.4) .
To further investigate, if aberrant DNA methylation of SLC16A3 is independent of the VHL genotype, we analysed data of the TCGA-cohort (available for 199 of the 283 samples; 70%). DNA methylation was not significantly dependent on the VHL status (carriers vs. non-carriers of mutations) of the patients (Supplementary Figure   S4) .
Evaluation of SLC16A3 promoter methylation as predictive marker for ccRCC outcome
Univariate Cox regression analyses were performed and the predictive ability of different models was estimated by calculating Harrell`s c-index (Supplementary Table   S5 ). The pathologic features T, M, and G were able to significantly predict cancerspecific survival in both the TuCP1-and TuCP2-cohort, whereas N and necrosis were only predictive in one of the cohorts (Supplementary Table S5 ). In line, overall survival could be predicted in the TCGA-cohort by T, M, G, and necrosis. DNA 
Discussion:
Since ccRCC is estimated to be mainly a metabolic disease and a clear example of the Warburg effect in tumor metabolism, we aimed to comprehensively study MCT4 expression as well as regulation by epigenetic mechanisms in ccRCC in order to evaluate its relevance as metabolic target for diagnosis, prognosis and potential therapy. In the present study, we found that MCT4 protein is significantly overexpressed in >85% of all ccRCCs in two independent cohorts. DNA methylation at specific CpGs in the SLC16A3 promoter correlated significantly inverse with MCT4 expression in ccRCC, which was also replicated. In addition, the regulation of MCT4 by DNA methylation was confirmed by reporter gene assays in four different renal carcinoma cell lines, strongly supporting the importance of DNA methylation for MCT4 expression.
Previous results from adenocarcinomas of the lung showed that high MCT4 expression is associated with aggressive tumor behavior (21) . Additionally, in mouse xenograft models of human colorectal and breast cancer, release of lactate from tumor cells through MCT4 (and not the isoform MCT1) is sufficient to increase tumor growth (22) . Moreover, lactate efflux mediated by MCT4, which can be explored in RCC cells by hyperpolarized 13C-pyruvate magnetic resonance, was significantly higher in a metastatic RCC cell line with increased MCT4 expression (12) . In line with these data MCT4 expression in ccRCC of our cohorts as well as DNA methylation at specific CpG units was strongly associated with various clinicopathological features, including sarcomatoid differentiation. Thus, both factors may be valuable parameters for diagnosis of high-grade tumors, and highly aggressive variants e.g. ccRCC with sarcomatoid differentiation and metastatic tumors. Table S5 ). Moreover, several reasons exist that the use of quantitative DNA methylation of SLC16A3 in ccRCC as potential novel prognostic predictor is more applicable compared to clinicopathological features. Quantification of DNA methylation by MALDI-TOF MS, but also other technologies (e.g. pyrosequencing), is a highly accurate and reliable method (18) , which has already been demonstrated for other biomarkers (25) . Potential inaccuracies in the determination of clinicopathological features are inevitable depending on the investigator and/or based on the absence of uniform grading systems for ccRCC resulting in inter-and intraindividual variability even for the most widely applied Fuhrmann grading system (26) .
Taken together, the association of DNA methylation and patient survival was observed not only in our cohort but also in the TCGA cohort, despite patients from different centers were included and some differences in the patient cohorts did exist.
Hence the association is apparently not dependent on the site of biospecimen`s recruitment, ethnicity of patients or the method used for quantification of DNA methylation, which further supports that MCT4 DNA methylation may serve as a novel biomarker in clinical practice . However, to definitely prove the importance of DNA methylation as a novel biomarker for prognosis, large-scale prospective studies are needed (27) . 
MCT4 targeting would be a therapeutic option irrespective of patients` VHL status.
Theoretically, MCT4 silencing could be achieved by MCT4 inhibitors. However, so far, only isoform specific MCT1 inhibitors (e.g. AR-C155858 (28)) have been evaluated in Phase I/II trials. Interestingly, treatment of patients with statins, which are known to inhibit MCT4 (29) , reduced the risk of RCC (30) . Thus, the development of isoform specific MCT4 inhibitors appears to be a promising therapeutic approach beneficial for several cancer types (e.g. breast cancer) (8) .
An alternative approach is targeting of MCT4 expression and thus lactate efflux by modulating DNA methylation. In contrast to the approved therapy of the myelodysplastic syndrome using DNA demethylating agents like 5-Azacytidine, specific MCT4 silencing by DNA methylation may be an attractive strategy for ccRCC treatment. It has recently been shown that zinc-finger proteins can target the DNA methyltransferase DNMT3a to specific promoter sites, resulting in stable reprogramming of breast cancer cells (31).
Our hypothesis generating, retrospective study has some limitations. First, we do not have complete data on treatment regimens for the study cohorts. However, when we compared patients with chemotherapy and targeted therapy in a small subgroup of the TCGA-cohort where treatment data were available, DNA methylation of SLC16A3 in ccRCC tissue was not significantly different. Moreover, a substantial proportion of patients in the TuCP1-cohort (86.5%) and TCGA-cohort (43.8%) was diagnosed before 2006, the time when targeted therapies were introduced into clinical practice (3), indicating that confounding of our results by novel therapeutic strategies is most unlikely. Second, genetic variants in SLC16A3 that might also alter variability of MCT4 expression, have not been investigated. 
In summary, we identified DNA methylation as a so far unknown underlying epigenetic mechanism for MCT4 regulation in ccRCC. Quantification of DNA methylation of specific CpG sites in the SLC16A3 promoter offers considerable clinical potential for diagnosis and prognosis of ccRCC. Large-scale studies are warranted to elucidate its clinical utility.
Research. Age at surgery for TuCP1 and TuCP2, age at initial pathologic diagnosis for TCGA. 3 Of note, all patients in the TuCP2-cohort died due to ccRCC; therefore, cancer-specific survival and overall survival is identical in this cohort. 4 Percentages do not sum up to 100% due to rounding. Unadjusted P-values. 2 Overall survival and cancer-specific survival is identical in the TuCP2-cohort. Abbreviations: T, primary tumor; N, regional lymph nodes; M, distant metastasis; G, grading; L, invasion into lymph vessels; V, invasion into veins; R, resection status Kaplan-Meier plots with cutoffs determined by conditional inference tree models show survival probability of the TCGA-cohort based on the DNA methylation status at CpG site cg18345635 in ccRCC tissue of the TCGA-cohort, discriminating between high (black) and low DNA methylation (grey), HR=0.39 (95% CI: 0.24-0.64). 
